Gastric acid and gastrin secretion after administration of the anti-inflammatory drug, sulindac, in man.
The effects of oral administration of the anti-inflammatory drug, (Z)-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidene]-indene-3-acetic acid (sulindac, Clinoril) 400 mg/d for 8 days, on basal and submaximal (3 micrograms/kg b.2. i.m.) and maximal (6 micrograms/kg b.w.) pentagastrin-stimulated gastric acid secretion as well as on serum gastrin concentration have been evaluated in female patients affected with osteoarthrosis. No significant changes in either gastric acid or gastrin secretion were induced by the treatment. Serum gastrin levels were also unaltered after acute administration of 200 mg sulindac. These results confirm and extend previous observations suggesting that the drug does not exert major actions on the stomach.
D000328:Adult; D000368:Aged; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000378:metabolism*; D006801:Humans; D007192:Indenes / Q000494:pharmacology*; D008875:Middle Aged; D010003:Osteoarthritis / Q000378:metabolism; D010418:Pentagastrin / Q000494:pharmacology; D013467:Sulindac / Q000494:pharmacology*; D013997:Time Factors
D005755:Gastrins; D007192:Indenes; D013467:Sulindac; D010418:Pentagastrin